Skip to main content
SpringerLink
Log in

Pharmacotherapy for Tobacco Dependence

  • Chapter
Nicotine Psychopharmacology

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 192))

Abstract

Pharmacotherapy can provide effective treatment of tobacco dependence and withdrawal, and thereby facilitate efforts to achieve and sustain tobacco abstinence. Currently approved medications for smoking cessation are nicotine replacement medications (NRT), including nicotine patch, gum, lozenge, sublin-gual tablet, inhaler and nasal spray, the antidepressant bupropion, and the nicotinic partial agonist varenicline. This review discusses the pharmacological basis for the use of these medications, and the properties that might contribute to their efficacy, safety, and abuse liability. The review also discusses how pharmacological principles can be used to improve existing medications, as well as assist in the development of new medications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  • American Psychiatric Association (1996) Practice guideline for the treatment of patients with nicotine dependence. Am J Psychiatry 153:1–31

    Google Scholar 

  • American Psychiatric Association (2000) Diagnostic and statistical manual – IVTR. American Psychiatric Association, Washington, DC

    Google Scholar 

  • Andreoli M, Tessari M, Pilla M, Valerio E, Hagan JJ, Heidbreder CA (2003) Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 28:1272–1280

    PubMed  CAS  Google Scholar 

  • Baldessarini RJ (2001) Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. In: Hardman JG, Limbird LE (eds) Goodman & Gilman's the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 447–483

    Google Scholar 

  • Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q (1993) Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol 22:1159–1167

    PubMed  CAS  Google Scholar 

  • Benowitz NL, Jacob P III (1984) Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 35:499–504

    PubMed  CAS  Google Scholar 

  • Benowitz NL, Jacob P III, Savanapridi C (1987) Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther 41:467–473

    PubMed  CAS  Google Scholar 

  • Benowitz NL, Zevin S, Jacob P III (1998) Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther 287:958–962

    PubMed  CAS  Google Scholar 

  • Bergstrom M, Nordberg A, Lunell E, Antoni G, Langstrom B (1995) Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin Pharmacol Ther 57:309–317

    PubMed  CAS  Google Scholar 

  • Black SC (2004) Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 5: 389–394

    PubMed  CAS  Google Scholar 

  • Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A (1999) Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ 318:285–289

    PubMed  CAS  Google Scholar 

  • Bruijnzeel AW, Markou A (2003) Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse 50:20–28

    PubMed  CAS  Google Scholar 

  • Buisson B, Bertrand D (2001) Chronic exposure to nicotine upregulates the human (alpha)4(beta)2 nicotinic acetylcholine receptor function. J Neurosci 21:1819–1829

    PubMed  CAS  Google Scholar 

  • Buisson B, Bertrand D (2002) Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol Sci 23:130–136

    PubMed  CAS  Google Scholar 

  • Charnaud B, Griffiths V (1952) Levels of intravenous drug misuse among clients prescribed oral dexamphetamine or oral methadone: a comparison. Drug Alcohol Depend 1998:79–84

    Google Scholar 

  • Choi JH, Dresler CM, Norton MR, Strahs KR (2003) Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 5:635–644

    PubMed  CAS  Google Scholar 

  • Cinciripini P, Wetter D, Tomlinson G, Tsoh J, De Moor C, Cinciripini L, Minna J (2004) The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob Res 6:229–239

    PubMed  CAS  Google Scholar 

  • Clarke PB (1993) Nicotine dependence–mechanisms and therapeutic strategies. Biochem Soc Symp 59:83–95

    PubMed  CAS  Google Scholar 

  • Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, Coletta AP (2004) Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resyn-chronisation therapy in heart failure. Eur J Heart Fail 6:501–508

    PubMed  Google Scholar 

  • Cohen LM, Collins FL, Britt DM (1997) The effect of chewing gum on tobacco withdrawal. Addict Behav 22:769–773

    PubMed  CAS  Google Scholar 

  • Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002) SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13:451–463

    PubMed  CAS  Google Scholar 

  • Cone EJ (1995) Pharmacokinetics and pharmacodynamics of cocaine. J Anal Toxicol 19:459–78

    PubMed  CAS  Google Scholar 

  • Cryan JF, Bruijnzeel AW, Skjei KL, Markou A (2003) Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharma-cology 168:347–358

    CAS  Google Scholar 

  • Curry SJ, Ludman EJ, McClure J (2003) Self-administered treatment for smoking cessation. J Clin Psychol 59:305–319

    PubMed  Google Scholar 

  • de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L (2002) Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr Res 56:47–54

    PubMed  Google Scholar 

  • de Villiers SH, Lindblom N, Kalayanov G, Gordon S, Malmerfelt A, Johansson AM, et al (2002) Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 69:247–253

    PubMed  CAS  Google Scholar 

  • Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML (2002) High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology 161:202–212

    PubMed  CAS  Google Scholar 

  • Edwards NB, Simmons RC, Rosenthal TL, Hoon PW, Downs JM (1988) Doxepin in the treatment of nicotine withdrawal. Psychomatics 29:203–206

    CAS  Google Scholar 

  • Edwards NB, Murphy JK, Downs AD, Ackerman BJ, Rosenthal TL (1989) Doxepin as an adjunct to smoking cessation: a double-blend pilot study. Am J Psychiatry 146:373–376

    PubMed  CAS  Google Scholar 

  • Evans SM, Cone EJ, Henningfield JE (1996) Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects. J Pharmacol Exp Ther 279:1345–1356

    PubMed  CAS  Google Scholar 

  • Fagerstrom KO, Schneider NG, Lunell E (1993) Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharma-cology 111:271–277

    CAS  Google Scholar 

  • Fant RV, Henningfield JE, Nelson RA, Pickworth WB (1999) Pharmacokinetics and pharmacody-namics of moist snuff in humans. Tob Control 8:387–392

    PubMed  CAS  Google Scholar 

  • Fant RV, Henningfield JE, Shiffman S, Strahs KR, Reitberg DP (2000) A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav 67:479–482

    PubMed  CAS  Google Scholar 

  • Fiore MC, Bailey WC, Cohen SJ, et al (2000) Treating tobacco use and dependence. Clinical practice guideline. US Department of Health and Human Services, Public Health Service, Rockville, MD

    Google Scholar 

  • Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, et al (1996a) Inhibition of monoamine oxidase B in the brains of smokers. Nature 379:733–736

    CAS  Google Scholar 

  • Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, et al (1996b) Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 93:14065–14069

    CAS  Google Scholar 

  • Gentry CL, Wilkins LH Jr, Lukas RJ (2003) Effects of prolonged nicotinic ligand exposure on function of heterologously expressed, human alpha4beta2- and alpha4beta2-nicotinic acetyl-choline receptors. J Pharmacol Exp Ther 304:206–216

    PubMed  CAS  Google Scholar 

  • Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB, Covey LS (1988) Heavy smokers, smoking cessation, and clonidine: Results of a double-blind, randomized trial. JAMA 259:2863–2866

    PubMed  CAS  Google Scholar 

  • Goldberg SR, Spealman RD, Risner ME, Henningfield JE (1983) Control of behavior by intravenous nicotine injections in laboratory animals. Pharmacol Biochem Behav 19:1011–1020

    PubMed  CAS  Google Scholar 

  • Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47–55

    PubMed  CAS  Google Scholar 

  • Gorsline J (1993) Nicotine pharmacokinetics of four nicotine transdermal systems. Health Values 17:20–24

    Google Scholar 

  • Gossop M (1988) Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 21:253–259

    PubMed  CAS  Google Scholar 

  • Gotti C, Moretti M, Gaimarri A, Zanardi A, Clementi F, Zoli M (2007) Heterogeneity and complexity of native brain nicotinic receptors. Biochem Pharmacol 74:1102–11

    PubMed  CAS  Google Scholar 

  • Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA (2004) Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 61:1107–1115

    PubMed  Google Scholar 

  • Hall SM, Reus VI, Munoz RF, Sees KL, Humfleet G, Hartz DT, Frederick S, Triffleman E (1998) Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 55:683–689

    PubMed  CAS  Google Scholar 

  • Hasman A, Holm S (2004) Nicotine conjugate vaccine: is there a right to a smoking future? J Med Ethics 30:344–345

    PubMed  CAS  Google Scholar 

  • Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, Horwith G, Pentel PR (2005) Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 78:456–467

    PubMed  CAS  Google Scholar 

  • Heading CE (2007) Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction. Curr Opin Investig Drugs 8:71–77

    PubMed  CAS  Google Scholar 

  • Henningfield JE (1995) Nicotine medications for smoking cessation. N Engl J Med 333:1196–1203

    PubMed  CAS  Google Scholar 

  • Henningfield JE, Benowitz NL (2004) Pharmacology and nicotine addiction. In: Boyle P, Gray N, Henningfield J, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp 129–147

    Google Scholar 

  • Henningfield JE, Miyasato K, Jasinski DR (1983) Cigarette smokers self-administer intravenous nicotine. Pharmacol Biochem Behav 19:887–890

    PubMed  CAS  Google Scholar 

  • Henningfield JE, Goldberg SR, Herning RI, Jasinski DR, Lukas SE, Miyasato KM, Nemeth-Coslett R, Pickworth WB, Rose JE, Sampson A, Snyder F (1986) Human studies of the behavioral pharmacological determinants of nicotine dependence. In: Harris LS (ed) Problems of drug dependence. National Institute on Drug Abuse, Rockville, MD, pp 54–65

    Google Scholar 

  • Henningfield JE, Keenan RM (1993) Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 61:743–750

    PubMed  CAS  Google Scholar 

  • Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED (1993) Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 33: 23–29

    PubMed  CAS  Google Scholar 

  • Henningfield JE, Fant RV, Gitchell J, Shiffman S (2000) Tobacco dependence. Global public health potential for new medications development and indications. Ann N Y Acad Sci 909:247–256

    PubMed  CAS  Google Scholar 

  • Henningfield J, Pankow J, Garrett B (2004) Ammonia and other chemical base tobacco additives and cigarette nicotine delivery: issues and research needs. Nicotine Tob Res 6:199–205

    PubMed  CAS  Google Scholar 

  • Herrera N, Franco R, Herrera L, Partidas A, Rolando R, Fagerstrom KO (1995) Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest 108:447–451

    PubMed  CAS  Google Scholar 

  • Houtsmuller EJ, Clemmey PA, Sigler LA, Stitzer ML (1997) Effects of naltrexone on smoking and abstinence. In: Harris LS (ed) Problems of drug dependence 1996: Proceedings of the 58th Annual Scientific Meeting. NIDA Research Monograph 174. National Institutes of Health, Rockville, MD

    Google Scholar 

  • Hughes JR, Hatsukami D (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43:289–294

    PubMed  CAS  Google Scholar 

  • Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR et al (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691

    PubMed  CAS  Google Scholar 

  • Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56–63

    PubMed  CAS  Google Scholar 

  • Klesges RC, Meyers AW, Klesges LM, La Vasque ME (1989) Smoking, body weight, and their effects on smoking behavior: a comprehensive review of the literature. Psychol Bull 106: 204–230

    PubMed  CAS  Google Scholar 

  • Klesges RC, Winders SE, Meyers AW, Eck LH, Ward KD, Hultquist CM, Ray JW, Shadish WR (1997) How much weight gain occurs following smoking cessation? A comparison of weight gain using both continuous and point prevalence abstinence. J Consult Clin Psychol 65: 286–291

    PubMed  CAS  Google Scholar 

  • Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G (1995) Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 24:41–47

    PubMed  CAS  Google Scholar 

  • Kreek MJ (1979) Methadone in treatment: physiological and pharmacological issues. In: Dupont RI, Goldstein A, O'Donnell J (eds) Handbook on drug abuse. National Institute on Drug Abuse, Rockville, MD, pp 57–86

    Google Scholar 

  • Le Foll B, Schwartz JC, Sokoloff P (2003) Disruption of nicotine conditioning by dopamine D(3) receptor ligands. Mol Psychiatry 8:225–230

    PubMed  Google Scholar 

  • Le Foll B, Sokoloff P, Stark H, Goldberg SR (2005) Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 30:720–730

    PubMed  Google Scholar 

  • Lerman C, Lesage MG, Perkins KA, O'Malley SS, Siegel SJ, Benowitz NL, Corrigall WA (2007) Translational research in medication development for nicotine dependence. Nat Rev Drug Dis-cov 6:746–62

    CAS  Google Scholar 

  • LeSage MG, Keyler DE, Collins G, Pentel PR (2003) Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations. Psychopharmacology 170:278–286

    Google Scholar 

  • Lévesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, Sokoloff P (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89:8155–8159

    PubMed  Google Scholar 

  • Lindblom N, de Villiers SH, Kalayanov G, Gordon S, Johansson AM, Svensson TH (2002) Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 69:254–260

    PubMed  CAS  Google Scholar 

  • Lunell E, Molander L, Andersson SB (1997) Temperature dependency of the release and bioavail-ability of nicotine from a nicotine vapour inhaler; in vitro/ in vivo correlation. Eur J Pharmacol 52:495–500

    CAS  Google Scholar 

  • Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, Carter VA, Cunningham JS, Wilson OB (1992) Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav 43:779–784

    PubMed  CAS  Google Scholar 

  • Malin DH, Lake JR, Smith TD, Khambati HN, Myers-Paal RL, Montellano AL, Jennings RE, Erwin DS, Presley SE, Perales BA (2006) Bupropion attenuates nicotine abstinence syndrome in the rat. Psychopharmacol 184:494–503

    CAS  Google Scholar 

  • Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann SF, et al (1992) Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J Neu-rosci 12:2765–2784

    CAS  Google Scholar 

  • Marks MJ, Grady SR, Collins AC (1993) Downregulation of nicotinic receptor function after chronic nicotine infusion. J Pharmacol Exp Ther 266:1268–1276

    PubMed  CAS  Google Scholar 

  • Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, Renner WA, Müller P, Bachmann MF (2005) A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 35:2031–2040

    PubMed  CAS  Google Scholar 

  • Mayo-Smith MF (1998) Management of alcohol intoxication and withdrawal. Principles of addiction medicine, 2nd edn. American Society of Addiction Medicine, Chevy Chase, MD, pp 431–440

    Google Scholar 

  • Mihalak KB, Carroll FI, Luetje CW (2006) Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70:801–805

    PubMed  CAS  Google Scholar 

  • Molander L, Lunell E (2001) Pharmacokinetic investigation of a nicotine sublingual tablet. Eur J Clin Pharmacol 56:813–819

    PubMed  CAS  Google Scholar 

  • Molander L, Lunell E, Andersson SB, Kuylenstierna F (1996) Dose released and absolute bioavail-ability of nicotine from a nicotine vapor inhaler. Clin Pharmacol Ther 59:394–400

    PubMed  CAS  Google Scholar 

  • Murphy JK, Edwards NB, Downs AD, Ackerman BJ, Rosenthal TL (1990) Effects of doxepin on withdrawal symptoms in smoking cessation. Am J Psychiatry 147:1353–1357

    PubMed  CAS  Google Scholar 

  • Nabi Biopharmaceuticals (2007). Nabi biopharmaceuticals announces positive results of phase IIb trial of NicVAX. Medical News Today, 3 May 2007. See http://www.medicalnewstoday.com/articles/69666.php, accessed October 11, 2007

  • Nemeth-Coslett R, Henningfield JE (1986) Effects of nicotine chewing gum on cigarette smoking and subjective and physiologic effects. Clin Pharmacol Ther 39:625–630

    Google Scholar 

  • Nemeth-Coslett R, Henningfield JE, O'Keeffe MK, Griffiths RR (1986) Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology 88:420–425

    Google Scholar 

  • Niaura RS, Goldstein MG, Depue JD, Keuthen NJ, Kristeller J, Abrams DB (1995) Fluoxetine, symptoms of depression, and smoking cessation. Ann Behav Med 17(Supp1):S061

    Google Scholar 

  • Pak AC, Ashby CR Jr, Heidbreder CA, Pilla M, Gilbert J, Xi ZX, Gardner EL (2006) The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 9:585–602

    PubMed  CAS  Google Scholar 

  • Parrott S, Godfrey C, Raw M, West R, McNeill A (1998) Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority. Thorax 53(Suppl 5 Pt 2):S1–S38

    PubMed  Google Scholar 

  • Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR et al (2000) A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 65:191–198

    PubMed  CAS  Google Scholar 

  • Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761–775

    PubMed  CAS  Google Scholar 

  • Picciotto MR (1998) Common aspects of the action of nicotine and other drugs of abuse. Drug Alcohol Depend 51:165–172

    PubMed  CAS  Google Scholar 

  • Pickworth WB, Bunker EB, Henningfield JE (1994) Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacology 115:9–14

    PubMed  CAS  Google Scholar 

  • Pomerleau OF, Pomerleau CS, Morrell EM, Lowenbergh JM (1991) Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake. Psychoneuroendocrinology 16:433–440

    PubMed  CAS  Google Scholar 

  • Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D (1998) A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 158:2035–2039

    PubMed  CAS  Google Scholar 

  • Puska P, Korhonen H, Vartiainen E, Urjanheimo E, Gustavsson G, Westin A (1995) Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tob Control 4:231–235

    Google Scholar 

  • Quick MW, Lester RA (2002) Desensitization of neuronal nicotinic receptors. J Neurobiol 53: 457–478

    PubMed  CAS  Google Scholar 

  • Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV (1994) Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 56:86–99

    PubMed  CAS  Google Scholar 

  • Ross JT, Corrigall WA, Heidbreder CA, LeSage MG (2007) Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. Eur J Pharmacol 559:173–179

    PubMed  CAS  Google Scholar 

  • Rowell PP, Wonnacott S (1990) Evidence for functional activity of up-regulated nicotine binding sites in rat striatal synaptosomes. J Neurochem 55:2105–2110

    PubMed  CAS  Google Scholar 

  • Royal College of Physicians (2000) Nicotine addiction in Britain: a report of the tobacco advisory group of the royal college of physicians. Royal College of Physicians of London, London

    Google Scholar 

  • Sayette MA, Shiffman S, Tiffany ST, Niaura RS, Martin CS, Shadel WG (2000) The measurement of drug craving. Addiction 95(Suppl 2):S189–S210

    PubMed  Google Scholar 

  • Schneider NG, Lunell E, Olmstead RE, Fagerstrom KO (1996) Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet 31:65–80

    PubMed  CAS  Google Scholar 

  • Schuh KJ, Schuh LM, Henningfield JE, Stitzer ML (1997) Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology 130:352–361

    PubMed  CAS  Google Scholar 

  • Shiffman S, Gnys M, Richards TJ, Paty JA, Hickcox M, Kassel JD (1996a) Temptations to smoke after quitting: a comparison of lapsers and maintainers. Health Psychol 15:455–461

    CAS  Google Scholar 

  • Shiffman S, Paty JA, Gnys M, Kassel JA, Hickcox M (1996b) First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 64:366–379

    CAS  Google Scholar 

  • Shiffman S, Engberg JB, Paty JA, Perz WG, Gnys M, Kassel JD, Hickcox M (1997) A day at a time: predicting smoking lapse from daily urge. J Abnorm Psychol 106:104–116

    PubMed  CAS  Google Scholar 

  • Shiffman S, Shadel WG, Niaura R, Khayrallah MA, Jorenby DE, Ryan CF, Ferguson CL (2003) Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology 166:343–350

    PubMed  CAS  Google Scholar 

  • Siu EC, Tyndale RF (2007) Non-nicotinic therapies for smoking cessation. Annu Rev Pharmacol Toxicol 47:541–64

    PubMed  CAS  Google Scholar 

  • Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321–327

    PubMed  CAS  Google Scholar 

  • Spring B, Wurtman RJ, Wurtman R, El-Khoury A, Goldberg H, McDermott J, Pingitore R (1995) Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. Am J Clin Nutr 62:1181–1187

    PubMed  CAS  Google Scholar 

  • Steinberg MB, Foulds J (2007) Rimonabant for treating tobacco dependence. Vasc Health Risk Manag 3:307–311

    PubMed  CAS  Google Scholar 

  • Sutherland G, Stapleton JA, Russell MAH, Feyerabend C (1995) Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology 120:418–425

    PubMed  CAS  Google Scholar 

  • Sweeney CT, Fant RV, Fagerstrom KO, McGovern JF, Henningfield JE (2001) Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 15:453–467

    PubMed  CAS  Google Scholar 

  • Tennant FS, Tarver AL, Rawason RA (1983) Clinical evaluation of mecamylamine for withdrawal from nicotine dependence. In: Harris LS (ed) Problems of drug dependence. NIDA Research Monograph 49. USDHHS publication no. 84-1316, pp 239–246

    Google Scholar 

  • Tercyak KP, Lerman C, Audrain J (2002) Association of attention-deficit/hyperactivity disorder symptoms with levels of cigarette smoking in a community sample of adolescents. J Am Acad Child Adolesc Psychiatry 41:799–805

    PubMed  Google Scholar 

  • Tiffany ST, Cox LS, Elash CA (2000) Effects of transdermal nicotine patches on abstinence-induced and cue- elicited craving in cigarette smokers. J Consult Clin Psychol 68:233–240

    PubMed  CAS  Google Scholar 

  • Tonnesen P (1988) Dose and nicotine dependence as determinants of nicotine gum efficacy. Prog Clin Biol Res 261:129–144

    PubMed  CAS  Google Scholar 

  • US Department of Health and Human Services (1988) The health consequences of smoking: Nicotine addiction, a report of the Surgeon General. Office of the Surgeon General, USDHHS, Rockville, MD

    Google Scholar 

  • U.S. Department of Health and Human Services (2000) Management of nicotine addiction. Reducing tobacco use: a report of the Surgeon General. Office of the Surgeon General, USDHHS, Rockville, MD

    Google Scholar 

  • Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876–880

    PubMed  CAS  Google Scholar 

  • Wagena EJ, Knipschild P, Zeegers MP (2005) Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 100:317–326

    PubMed  CAS  Google Scholar 

  • Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH (2004) Cue-provoked craving and nicotine replacement therapy in smoking cessation. J Consult Clin Psychol 72:1136–1143

    PubMed  Google Scholar 

  • West RJ, Jarvis MJ, Russell MA, Carruthers ME, Feyerabend C (1984) Effect of nicotine replacement on the cigarette withdrawal syndrome. Br J Addict 79:215–219

    PubMed  CAS  Google Scholar 

  • World Bank (1999). Curbing the epidemic: governments and the economics of tobacco control. The International Bank for Reconstruction and Development, The World Bank, Washington, DC

    Google Scholar 

  • World Health Organization (1992) The ICD-10 classification of mental behavioural disorders. World Health Organization, Geneva

    Google Scholar 

  • World Health Organization (2003) Policy recommendations for smoking cessation and treatment of tobacco dependence. World Health Organization, Geneva

    Google Scholar 

  • Xenova Group PLC (2005). Anti-smoking vaccine TA-NIC preliminary 12 month clinical trial results. Press release, 3 March 2005. See http://www.xenova.co.uk/PressReleases/ pr 20050303 02.html, accessed 11 October 2007

Download references

Authors
  1. Reginald V. Fant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. August R. Buchhalter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Albert C. Buchman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jack E. Henningfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pinney Associates, 3 Bethesda Metro Center, Bethesda, MD, 20814-3472, USA

    Jack E. Henningfield

  2. UCLA Semel Institute for Neuroscience and Human Behavior, 760 Westwood Plaza, Los Angeles, CA, 90024-1759, USA

    Edythe D. London

  3. Center for Brain Research, Bornova, Ege University, Izmir, 35100, Turkey

    Sakire Pogun

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fant, R.V., Buchhalter, A.R., Buchman, A.C., Henningfield, J.E. (2009). Pharmacotherapy for Tobacco Dependence. In: Henningfield, J.E., London, E.D., Pogun, S. (eds) Nicotine Psychopharmacology. Handbook of Experimental Pharmacology, vol 192. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69248-5_17

Download citation

Publish with us

Policies and ethics

Search

Navigation